4 citations
,
April 2020 in “medRxiv (Cold Spring Harbor Laboratory)” Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.
COVID-19 can cause significant hair loss.
Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.
7 citations
,
April 2007 in “PubMed” Finasteride, a hair loss drug, caused a skin rash that went away when the drug was stopped and returned when used again.
7 citations
,
May 2022 in “The Journal of Dermatology” Hair loss is a frequent long-term effect of COVID-19, and oral minoxidil is the most common effective treatment.
12 citations
,
May 2016 in “British Journal of Dermatology” A 6-year-old boy's skin condition improved after stopping a specific treatment and starting new medications.
1 citations
,
March 2000 in “PubMed” A 16-year-old boy's alopecia areata progressed unusually to resemble male pattern baldness.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
February 2026 in “The Journal of Sexual Medicine” GnRH agonists can help manage recurrent priapism in sickle cell patients, but long-term safety is unclear.
May 2025 in “The Journal of Rheumatology” SLE can cause unusual gastrointestinal symptoms, and immunosuppressive therapy can be effective.
Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.
2 citations
,
January 2024 in “European Journal of Case Reports in Internal Medicine” Beau's lines on fingernails might indicate past severe COVID-19 and risk of reinfection.
23 citations
,
November 2024 in “Nature” 
1 citations
,
January 2018 in “ARC Journal of Dermatology” A patient had both chronic lupus and systemic scleroderma, requiring careful treatment to manage symptoms.
3 citations
,
March 2014 in “Annals of Hepatology” A man lost all his hair after stopping hepatitis C treatment and it didn't grow back.
1 citations
,
October 2024 in “JCEM Case Reports” 5α-reductase deficiency can cause ambiguous genitalia and gender dysphoria, treatable with testosterone.
10 citations
,
August 1998 in “Journal of Investigative Dermatology” 
May 2022 in “Liver transplantation” The document explains how the immune system reacts to organ transplants and the treatments used to prevent rejection.
1 citations
,
September 2022 in “TURKDERM” Systemic retinoids do not increase COVID-19 risk or severity.
33 citations
,
October 2018 in “BMJ Case Reports” Aggressive treatment in young patients with certain drug reactions may lead to multiple autoimmune diseases later.
40 citations
,
April 2018 in “Endocrine” PFS and PSSD are similar conditions with persistent sexual dysfunction after stopping medication.
2 citations
,
November 2024 in “JAAD Case Reports” This document reports a case of a woman in her sixties with metastatic squamous cell carcinoma who experienced alopecia areata (AA) and global hair repigmentation as immune-related adverse events (irAEs) during anti-PD-L1 immunotherapy. The patient developed AA 15 months after starting combination immunotherapy, which is later than the typical onset. She was treated with intralesional triamcinolone, resulting in full hair regrowth and unexpected generalized hair repigmentation, returning to her original hair color without external dyes. This case highlights the rare occurrence of simultaneous AA and hair repigmentation as irAEs, suggesting a disruption of hair follicle immune privilege due to PD-L1 blockade. The study emphasizes the importance of recognizing and managing irAEs to maintain patients on immunotherapy, noting that intralesional steroids can effectively restore hair growth and improve quality of life.
32 citations
,
October 2004 in “Pharmacotherapy” Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
February 2024 in “BMJ Open” The study concluded that different treatments reduced post-COVID symptoms over time and that factors like age, severity, and comorbidities affect symptom risk.
1 citations
,
August 2022 in “Rheumatology (Bulgaria)” A woman experienced severe symptoms, including hair loss, after a COVID-19 vaccine, suggesting a possible autoimmune reaction.
1 citations
,
August 2021 in “International Journal of Dermatology” The LGBT-focused curriculum improved dermatology residents' confidence in treating LGBT patients.
34 citations
,
April 2008 in “Journal of the European Academy of Dermatology and Venereology” Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.
February 2026 in “Cureus” Ciclosporin can cause excessive hair growth even with testosterone blockers.
9 citations
,
November 2012 in “Hepatology Research” A man lost all his hair permanently after hepatitis C treatment, a side effect not seen before.
March 2016 in “International Journal of Infectious Diseases” Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.